ARTICLE | Clinical News
Edoxaban: Phase III data
December 13, 2010 8:00 AM UTC
The double-blind, double-dummy, Japanese Phase III STARS J-V trial in 610 patients undergoing total hip replacement surgery showed that once-daily 30 mg oral edoxaban for 11-14 days was superior to tw...